Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 May;38(5):715-724.
doi: 10.1007/s00296-018-4021-5. Epub 2018 Apr 7.

Clinical connection between rheumatoid arthritis and liver damage

Affiliations
Review

Clinical connection between rheumatoid arthritis and liver damage

Biljana Radovanović-Dinić et al. Rheumatol Int. 2018 May.

Abstract

When liver damage is present in rheumatoid arthritis (RA) patients, it is sometimes difficult to determine whether it is a hepatic manifestation of RA, associated primary liver disease or hepatotoxic liver disease which developed during the treatment of RA. Liver damage during RA is most common in the form of asymptomatic abnormal liver tests. Occasionally, liver damage may progress to cirrhosis. Patients with RA are more susceptible to an associated autoimmune liver disease. Medications used in rheumatology are often hepatotoxic and it is difficult to differentiate between hepatic manifestations of the primary disease and potential hepatotoxicity of the administered medications. The significance of the paper is in the fact that it includes the most relevant and the latest information on this commonly present problem in clinical practice. The aim of the author is to provide comprehensive but at the same time concise data which will be useful to the doctors who come into contact with RA patients with symptomatic or asymptomatic liver disease. Timely diagnosis and treatment of liver disease in RA patients can significantly influence the course and outcome of rheumatoid arthritis.

Keywords: Arthritis; Biological therapy; Hepatitis; Liver; Rheumatoid.

PubMed Disclaimer

References

    1. Aliment Pharmacol Ther. 2004 Feb 15;19(4):391-9 - PubMed
    1. Nat Rev Gastroenterol Hepatol. 2010 May;7(5):251-64 - PubMed
    1. Rheumatol Int. 1997;17(1):11-6 - PubMed
    1. Ann Rheum Dis. 2010 Jan;69(1):43-7 - PubMed
    1. J Gastroenterol. 2002;37(8):617-25 - PubMed

MeSH terms

Substances

LinkOut - more resources